Oncopeptides AB (0RN4) Ratios
2 Followers
Oncopeptides AB Ratios
GB:0RN4's free cash flow for Q2 2026 was kr-42.81M. For the 2026 fiscal year, GB:0RN4's free cash flow was increased by kr0.00 and operating cash flow was kr-42.81M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.63 | 4.23 | 4.52 | 4.25 | 1.83 |
| Quick Ratio | 2.45 | 4.14 | 4.46 | 4.25 | 1.83 |
| Cash Ratio | 1.85 | 3.48 | 3.86 | 4.02 | 1.61 |
| Solvency Ratio | -1.24 | -1.45 | -1.31 | -3.52 | -6.17 |
| Operating Cash Flow Ratio | -5.01 | -5.07 | -6.22 | -4.91 | -6.73 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -70.10 | -138.02 |
| Net Current Asset Value | kr -76.57M | kr 27.17M | kr 21.30M | kr 273.00M | kr 183.87M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.03 | 0.58 | 0.53 | 0.02 | 0.03 |
| Debt-to-Equity Ratio | -2.37 | 2.61 | 2.22 | 0.03 | 0.07 |
| Debt-to-Capital Ratio | 1.73 | 0.72 | 0.69 | 0.03 | 0.06 |
| Long-Term Debt-to-Capital Ratio | 1.87 | 0.69 | 0.65 | 0.00 | 0.00 |
| Financial Leverage Ratio | -2.29 | 4.50 | 4.20 | 1.31 | 2.08 |
| Debt Service Coverage Ratio | -15.27 | -20.71 | -40.15 | -46.48 | -117.97 |
| Interest Coverage Ratio | -15.63 | -22.40 | -43.81 | -395.64 | -1498.86 |
| Debt to Market Cap | 0.12 | 0.47 | 0.15 | 0.01 | 0.02 |
| Interest Debt Per Share | 0.68 | 0.93 | 1.04 | 0.13 | 0.20 |
| Net Debt to EBITDA | -0.26 | 0.14 | 0.20 | 1.05 | 0.25 |
| Profitability Margins | |||||
| Gross Profit Margin | 82.96% | 91.59% | 103.06% | 99.93% | 55.09% |
| EBIT Margin | -321.75% | -858.04% | -688.99% | -4031.08% | -1200.75% |
| EBITDA Margin | -308.30% | -827.24% | -657.64% | -3825.43% | -1182.69% |
| Operating Profit Margin | -317.62% | -895.78% | -719.61% | -4181.33% | -1201.16% |
| Pretax Profit Margin | -348.95% | -898.03% | -705.41% | -4041.65% | -1201.55% |
| Net Profit Margin | -350.94% | -899.29% | -707.30% | -4044.90% | -1209.11% |
| Continuous Operations Profit Margin | -350.94% | -899.29% | -707.30% | -4044.90% | -1209.11% |
| Net Income Per EBT | 100.57% | 100.14% | 100.27% | 100.08% | 100.63% |
| EBT Per EBIT | 109.86% | 100.25% | 98.03% | 96.66% | 100.03% |
| Return on Assets (ROA) | -185.10% | -116.55% | -104.50% | -87.71% | -325.53% |
| Return on Equity (ROE) | 423.81% | -524.28% | -438.73% | -114.83% | -678.30% |
| Return on Capital Employed (ROCE) | -250.05% | -147.01% | -131.02% | -116.59% | -663.71% |
| Return on Invested Capital (ROIC) | -230.36% | -141.67% | -127.63% | -112.10% | -601.93% |
| Return on Tangible Assets | -185.10% | -116.55% | -104.50% | -87.71% | -326.58% |
| Earnings Yield | -22.87% | -109.62% | -35.97% | -47.41% | -317.14% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.33 | 2.84 | 16.05 | 0.48 | 7.71 |
| Payables Turnover | 17.29 | 0.15 | -0.07 | 0.00 | 1.49 |
| Inventory Turnover | 1.47 | 0.61 | -0.44 | 0.00 | 0.00 |
| Fixed Asset Turnover | 4.02 | 1.17 | 1.02 | 0.41 | 4.78 |
| Asset Turnover | 0.53 | 0.13 | 0.15 | 0.02 | 0.27 |
| Working Capital Turnover Ratio | 0.60 | 0.20 | 0.16 | 0.04 | 0.33 |
| Cash Conversion Cycle | 311.55 | -1763.01 | 4285.02 | -1715901.46 | -197.96 |
| Days of Sales Outstanding | 84.35 | 128.47 | 22.74 | 754.38 | 47.36 |
| Days of Inventory Outstanding | 248.31 | 599.10 | -820.32 | 0.00 | 0.00 |
| Days of Payables Outstanding | 21.11 | 2490.58 | -5082.60 | 1716655.83 | 245.31 |
| Operating Cycle | 332.66 | 727.57 | -797.58 | 754.38 | 47.36 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.98 | -1.57 | -2.20 | -5.11 | -20.14 |
| Free Cash Flow Per Share | -0.98 | -1.57 | -2.20 | -5.14 | -20.14 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -729.89 | -2409.42 | -167.73 | -4473.13 |
| Capital Expenditure Coverage Ratio | 0.00 | -729.89 | -2409.42 | -167.73 | -4473.13 |
| Operating Cash Flow Coverage Ratio | -1.60 | -1.84 | -2.22 | -44.07 | -106.84 |
| Operating Cash Flow to Sales Ratio | -3.13 | -8.23 | -7.94 | -50.33 | -12.82 |
| Free Cash Flow Yield | -20.42% | -100.36% | -40.38% | -59.34% | -336.30% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.37 | -0.91 | -2.78 | -2.11 | -0.32 |
| Price-to-Sales (P/S) Ratio | 15.35 | 8.20 | 19.66 | 85.33 | 3.81 |
| Price-to-Book (P/B) Ratio | -18.53 | 4.78 | 12.20 | 2.42 | 2.14 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.90 | -1.00 | -2.48 | -1.69 | -0.30 |
| Price-to-Operating Cash Flow Ratio | -4.90 | -1.00 | -2.48 | -1.70 | -0.30 |
| Price-to-Earnings Growth (PEG) Ratio | 0.12 | 0.07 | 0.05 | 0.03 | 0.01 |
| Enterprise Value Multiple | -5.24 | -0.85 | -2.79 | -1.18 | -0.07 |
| Enterprise Value | 1.15B | 222.82M | 645.27M | 377.92M | 103.01M |
| EV to EBITDA | -5.24 | -0.85 | -2.79 | -1.18 | -0.07 |
| EV to Sales | 16.15 | 7.04 | 18.32 | 45.23 | 0.87 |
| EV to Free Cash Flow | -5.15 | -0.86 | -2.31 | -0.89 | -0.07 |
| EV to Operating Cash Flow | -5.15 | -0.86 | -2.31 | -0.90 | -0.07 |
| Tangible Book Value Per Share | -0.26 | 0.33 | 0.45 | 3.57 | 2.78 |
| Shareholders’ Equity Per Share | -0.26 | 0.33 | 0.45 | 3.57 | 2.80 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | -0.00 | -0.00 | -0.00 | -0.01 |
| Revenue Per Share | 0.31 | 0.19 | 0.28 | 0.10 | 1.57 |
| Net Income Per Share | -1.10 | -1.71 | -1.96 | -4.11 | -19.00 |
| Tax Burden | 1.01 | 1.00 | 1.00 | 1.00 | 1.01 |
| Interest Burden | 1.08 | 1.05 | 1.02 | 1.00 | 1.00 |
| Research & Development to Revenue | 1.40 | 3.83 | 3.04 | 26.05 | 5.75 |
| SG&A to Revenue | 2.74 | 6.23 | 1.96 | 10.06 | 1.48 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 2.29 | -0.29 |
| Income Quality | 0.89 | 0.92 | 1.12 | 1.20 | 1.07 |
Currency in SEK
